Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
40.11 (1y: +2%)
Market Cap 33.94 B P/E(ttm) 20.00
Enterprise Value 45.31 B P/B 1.50
TEVA- NYSE (USA)
Teva Pharmaceutical Industries Ltd
  • Currently 4.5/5
Business Predictability Rank: 4.5-Star
Back Testing Results:
Average gain of all 4.5-Star stocks: 10.6% per year.
% of Stocks that are in still loss if held for 10yrs: 10%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$40.11
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.196
TEVA's Cash to Debt is ranked lower than
88% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. TEVA: 0.196 )
TEVA' s 10-Year Cash to Debt Range
Min: 0.08   Max: 1.03
Current: 0.2
0.08
1.03
Equity to Asset -0.076
TEVA's Equity to Asset is ranked lower than
94% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. TEVA: -0.076 )
TEVA' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.4
Current: -0.08
-0.13
0.4
Interest Coverage 6.2
TEVA's Interest Coverage is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. TEVA: 6.2 )
TEVA' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: 6.2
F-Score: 6
Z-Score: 1.73
M-Score: -3.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 10.90
TEVA's Operating margin (%) is ranked lower than
75% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. TEVA: 10.90 )
TEVA' s 10-Year Operating margin (%) Range
Min: 9.5   Max: 26.8
Current: 10.9
9.5
26.8
Net-margin (%) 9.7
TEVA's Net-margin (%) is ranked lower than
75% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. TEVA: 9.7 )
TEVA' s 10-Year Net-margin (%) Range
Min: 5.7   Max: 21.1
Current: 9.7
5.7
21.1
ROE (%) 8.6
TEVA's ROE (%) is ranked lower than
73% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. TEVA: 8.6 )
TEVA' s 10-Year ROE (%) Range
Min: 3.9   Max: 22.4
Current: 8.6
3.9
22.4
ROA (%) 3.9
TEVA's ROA (%) is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. TEVA: 3.9 )
TEVA' s 10-Year ROA (%) Range
Min: 1.9   Max: 11.7
Current: 3.9
1.9
11.7
ROC (Joel Greenblatt) (%) 22.30
TEVA's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. TEVA: 22.30 )
TEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15   Max: 47.4
Current: 22.3
15
47.4
Revenue Growth (%) 10.7
TEVA's Revenue Growth (%) is ranked higher than
90% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. TEVA: 10.7 )
TEVA' s 10-Year Revenue Growth (%) Range
Min: 10.4   Max: 17.1
Current: 10.7
10.4
17.1
EBITDA Growth (%) 4.9
TEVA's EBITDA Growth (%) is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.35 vs. TEVA: 4.9 )
TEVA' s 10-Year EBITDA Growth (%) Range
Min: -3.2   Max: 31.9
Current: 4.9
-3.2
31.9
EPS Growth (%) 0.2
TEVA's EPS Growth (%) is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. TEVA: 0.2 )
TEVA' s 10-Year EPS Growth (%) Range
Min: -16.3   Max: 47.7
Current: 0.2
-16.3
47.7
» TEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

TEVA Guru Trades in Q2 2012

George Soros 25,000 sh (New)
Richard Perry 3,315,000 sh (+1300.18%)
Jim Simons 688,363 sh (+1114.84%)
Steven Cohen 227,002 sh (+177.59%)
Vanguard Health Care Fund 7,050,000 sh (+138.98%)
David Dreman 98,135 sh (+33.6%)
NWQ Managers 7,837,726 sh (+17.65%)
Diamond Hill Capital 47,500 sh (+11.66%)
Tom Gayner 553,500 sh (+3.15%)
James Barrow 2,608,663 sh (+1.44%)
Jean-Marie Eveillard 200 sh (unchged)
Richard Perry 2,342,600 sh (unchged)
Bernard Horn 52,800 sh (unchged)
RS Investment Management Sold Out
David Rolfe Sold Out
John Paulson Sold Out
Daniel Loeb Sold Out
Ronald Muhlenkamp 290,660 sh (-0.04%)
Manning & Napier Advisors, Inc 190,300 sh (-1.28%)
Richard Snow 1,330,739 sh (-8.69%)
Pioneer Investments 1,710,557 sh (-12.3%)
Scott Black 36,240 sh (-17.16%)
» More
Q3 2012

TEVA Guru Trades in Q3 2012

Michael Price 100,000 sh (New)
George Soros 275,000 sh (+1000%)
Vanguard Health Care Fund 8,750,000 sh (+24.11%)
David Dreman 105,805 sh (+7.82%)
Tom Gayner 595,700 sh (+7.62%)
Jim Simons 699,163 sh (+1.57%)
Bernard Horn 52,800 sh (unchged)
Richard Perry 2,342,600 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Diamond Hill Capital 47,500 sh (unchged)
Manning & Napier Advisors, Inc 190,300 sh (unchged)
Richard Perry Sold Out
Ronald Muhlenkamp 288,175 sh (-0.85%)
James Barrow 2,552,463 sh (-2.15%)
NWQ Managers 7,525,031 sh (-3.99%)
Scott Black 34,775 sh (-4.04%)
Pioneer Investments 1,484,338 sh (-13.22%)
Richard Snow 1,128,139 sh (-15.22%)
Steven Cohen 41,749 sh (-81.61%)
» More
Q4 2012

TEVA Guru Trades in Q4 2012

John Burbank 75,000 sh (New)
Steven Cohen 150,465 sh (+260.4%)
Michael Price 350,000 sh (+250%)
Jim Simons 1,684,063 sh (+140.87%)
James Barrow 4,305,129 sh (+68.67%)
Vanguard Health Care Fund 10,021,100 sh (+14.53%)
David Dreman 117,667 sh (+11.21%)
Tom Gayner 644,100 sh (+8.12%)
Richard Snow 1,147,735 sh (+1.74%)
Manning & Napier Advisors, Inc 190,300 sh (unchged)
Richard Perry 2,342,600 sh (unchged)
Vanguard Health Care Fund 10,021,100 sh (unchged)
Bernard Horn 52,800 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
George Soros 40,000 sh (unchged)
Scott Black Sold Out
Ronald Muhlenkamp 285,460 sh (-0.94%)
Diamond Hill Capital 46,630 sh (-1.83%)
NWQ Managers 6,683,970 sh (-11.18%)
Pioneer Investments 1,105,702 sh (-25.51%)
George Soros 150,000 sh (-45.45%)
» More
Q1 2013

TEVA Guru Trades in Q1 2013

Bruce Kovner 31,800 sh (New)
James Barrow 7,078,456 sh (+64.42%)
David Dreman 137,438 sh (+16.8%)
Vanguard Health Care Fund 11,361,300 sh (+13.37%)
Richard Snow 1,278,104 sh (+11.36%)
Tom Gayner 663,600 sh (+3.03%)
Jim Simons 1,722,163 sh (+2.26%)
Ronald Muhlenkamp 287,810 sh (+0.82%)
Michael Price 350,000 sh (unchged)
Manning & Napier Advisors, Inc 190,300 sh (unchged)
George Soros 40,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Bernard Horn 52,800 sh (unchged)
John Burbank Sold Out
Diamond Hill Capital 46,530 sh (-0.21%)
NWQ Managers 6,097,377 sh (-8.78%)
Steven Cohen 121,135 sh (-19.49%)
Pioneer Investments 498,370 sh (-54.93%)
George Soros 50,000 sh (-66.67%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 Add 13.37%0.21%$37.19 - $41.06 $ 40.194%11361300
James Barrow 2013-03-31 Add 64.42%0.2%$37.19 - $41.06 $ 40.194%7078456
John Burbank 2013-03-31 Sold Out 0.11%$37.19 - $41.06 $ 40.194%0
George Soros 2013-03-31 Reduce -66.67%0.04%$37.19 - $41.06 $ 40.194%50000
Michael Price 2012-12-31 Add 250%1.36%$36.95 - $42.52 $ 40.191%350000
Scott Black 2012-12-31 Sold Out 0.21%$36.95 - $42.52 $ 40.191%0
James Barrow 2012-12-31 Add 68.67%0.13%$36.95 - $42.52 $ 40.191%4305129
John Burbank 2012-12-31 New Buy0.11%$36.95 - $42.52 $ 40.191%75000
George Soros 2012-12-31 Reduce -45.45%0.08%$36.95 - $42.52 $ 40.191%150000
Richard Perry 2012-09-30 Sold Out 5.3%$39.27 - $42.34 $ 40.19-1%0
Michael Price 2012-09-30 New Buy0.61%$39.27 - $42.34 $ 40.19-1%100000
Vanguard Health Care Fund 2012-09-30 Add 24.11%0.31%$39.27 - $42.34 $ 40.19-1%8750000
George Soros 2012-09-30 Add 1000%0.16%$39.27 - $42.34 $ 40.19-1%275000
Richard Perry 2012-06-30 Add 1300.18%4.92%$37.55 - $45.98 $ 40.19-4%3315000
Daniel Loeb 2012-06-30 Sold Out 0.89%$37.55 - $45.98 $ 40.19-4%0
Vanguard Health Care Fund 2012-06-30 Add 138.98%0.76%$37.55 - $45.98 $ 40.19-4%7050000
John Paulson 2012-06-30 Sold Out 0.04%$37.55 - $45.98 $ 40.19-4%0
David Dreman 2012-06-30 Add 33.6%0.02%$37.55 - $45.98 $ 40.19-4%98135
George Soros 2012-06-30 New Buy0.01%$37.55 - $45.98 $ 40.19-4%25000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Guru Stocks at 52-Week Lows: NTT, TEVA, NEM, SE, FE
January 28, 2013
According to GuruFocus list of 52-week lows, these Guru stocks are trading at or near their lowest price in the past 52 weeks. Read more...
Stocks to Buy on Dips: Teva
December 27, 2012
- Stocks To Buy On Dips: Teva
I have been buying Teva (TEVA) stock. Read more...
Guru Stocks at 52-Week Lows: VOD, TEVA, NEM, DVN, SE
December 24, 2012
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 20.00
TEVA's P/E(ttm) is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.76 vs. TEVA: 20.00 )
TEVA' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 938.25
Current: 20
10.53
938.25
P/B 1.50
TEVA's P/B is ranked higher than
81% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TEVA: 1.50 )
TEVA' s 10-Year P/B Range
Min: 1.37   Max: 9.01
Current: 1.5
1.37
9.01
P/S 1.73
TEVA's P/S is ranked higher than
66% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. TEVA: 1.73 )
TEVA' s 10-Year P/S Range
Min: 1.6   Max: 5.94
Current: 1.73
1.6
5.94
PFCF 9.20
TEVA's PFCF is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. TEVA: 9.20 )
TEVA' s 10-Year PFCF Range
Min: 8.45   Max: 203.3
Current: 9.2
8.45
203.3
EV-to-EBIT 21.3
TEVA's EV-to-EBIT is ranked higher than
81% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. TEVA: 21.3 )
TEVA' s 10-Year EV-to-EBIT Range
Min: 11.9   Max: 987.7
Current: 21.3
11.9
987.7
PEG 1
TEVA's PEG is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. TEVA: 1 )
TEVA' s 10-Year PEG Range
Min: 0.41   Max: 96.43
Current: 1
0.41
96.43
Shiller P/E 15.7
TEVA's Shiller P/E is ranked higher than
92% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.12 vs. TEVA: 15.7 )
TEVA' s 10-Year Shiller P/E Range
Min: 14.08   Max: 75.19
Current: 15.7
14.08
75.19

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.36
TEVA's Dividend Yield is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. TEVA: 2.36 )
TEVA' s 10-Year Dividend Yield Range
Min: 0.12   Max: 2.34
Current: 2.36
0.12
2.34
Dividend Payout 0.4365
TEVA's Dividend Payout is ranked lower than
69% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.86 vs. TEVA: 0.4365 )
TEVA' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.53
Current: 0.44
0.05
0.53
Dividend growth (3y) 13.6
TEVA's Dividend growth (3y) is ranked higher than
99% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -0.95 vs. TEVA: 13.6 )
TEVA' s 10-Year Dividend growth (3y) Range
Min: 13.6   Max: 56
Current: 13.6
13.6
56
Yield on cost (5-Year) 5.75
TEVA's Yield on cost (5-Year) is ranked higher than
98% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. TEVA: 5.75 )
TEVA' s 10-Year Yield on cost (5-Year) Range
Min: 0.3   Max: 5.85
Current: 5.75
0.3
5.85
Share Buyback Rate 0.6
TEVA's Share Buyback Rate is ranked higher than
71% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.00 vs. TEVA: 0.6 )
TEVA' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -8.1
Current: 0.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 5
TEVA's Price/Net Current Asset Value is ranked higher than
59% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. TEVA: 5 )
TEVA' s 10-Year Price/Net Current Asset Value Range
Min: 4.7   Max: 13.4
Current: 5
4.7
13.4
Price/DCF (Projected) 0.6
TEVA's Price/DCF (Projected) is ranked higher than
73% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVA: 0.6 )
TEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 3.3
Current: 0.6
0.6
3.3
Price/Median PS Value 0.4
TEVA's Price/Median PS Value is ranked higher than
66% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.70 vs. TEVA: 0.4 )
TEVA' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.4
Current: 0.4
0.4
1.4
Price/Peter Lynch Fair Value 1.4
TEVA's Price/Peter Lynch Fair Value is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVA: 1.4 )
TEVA' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 10.2
Current: 1.4
0.6
10.2
Earnings Yield (Greenblatt) 4.70
TEVA's Earnings Yield (Greenblatt) is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. TEVA: 4.70 )
TEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.4
Current: 4.7
0.1
8.4
Forward Rate of Return (Yacktman) 20.7
TEVA's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.82 vs. TEVA: 20.7 )
TEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.3   Max: 37.6
Current: 20.7
8.3
37.6

Business Description

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Company Website
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF
Traded in other countries:TEVJF.USA, TEV.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial